NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 high patient population receiving G100+pembrolizumab (potential predictive biomarker) Responses occur in both recurrent/refractory and treatment-naïve patient populations Data presented at ASH 2017
View HTML
Toggle Summary Delaware Court of Chancery Decision Denies Theravectys Motion for Preliminary Injunction
SEATTLE & SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- Immune Design Corp. (Nasdaq: IMDZ), a clinical-stage immunotherapy company, today announced that the Delaware Court of Chancery yesterday denied Theravectys SA's ("TVS") request for a preliminary injunction that sought to enjoin Immune Design from
View HTML
Toggle Summary IMDZ Announces Filing of New Lawsuit by Theravectys SA
Repeats Some Claims Made by TVS in Prior Lawsuit That It Previously Voluntarily Dismissed
View HTML
Toggle Summary Immune Design Added to Russell 2000(R) Index
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today that the company was added to the Russell 2000 ® Index as part of Russell Investments' quarterly addition of select initial public offering (IPO) companies.
View HTML
Toggle Summary Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy
SEATTLE and SOUTH SAN FRANCISCO, Calif. and EMERYVILLE Calif,, May 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, and Gritstone Oncology, a private cancer immunotherapy company developing next-generation, personalized cancer
View HTML
Toggle Summary Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma
Phase 1 Trials to Evaluate Investigational Agents G100 or LV305 Combined With Merck's KEYTRUDA(R) (pembrolizumab)
View HTML
Toggle Summary Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development
Partner Sanofi commences dosing in peanut allergy Phase 1 trial leveraging GLAAS
View HTML
Toggle Summary Immune Design Announces Closing of Initial Public Offering
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the closing of its initial public offering of 5,000,000 shares, at a public offering price of $12.00 per share, resulting in aggregate gross proceeds of $60.0 million, before
View HTML
Toggle Summary Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent
Investigator-Sponsored Trial to Evaluate Combination of G100 With Local Radiation Therapy in Patients With Sarcoma
View HTML
Toggle Summary Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual
View HTML